TALAZOPARIB TOSYLATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H14F2N6O.C7H8O3S
Molecular Weight	552.552
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C=C1)S(O)(=O)=O.CN2N=CN=C2[C@@H]3[C@H](NC4=CC(F)=CC5=C4C3=NNC5=O)C6=CC=C(F)C=C6

InChI

InChIKey=QUQKKHBYEFLEHK-QNBGGDODSA-N

InChI=1S/C19H14F2N6O.C7H8O3S/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28;1-6-2-4-7(5-3-6)11(8,9)10/h2-8,15-16,24H,1H3,(H,26,28);2-5H,1H3,(H,8,9,10)/t15-,16-;/m1./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23881923http://adisinsight.springer.com/drugs/800033477
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26652717 | https://www.ncbi.nlm.nih.gov/pubmed/23881923 | https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm

Talazoparib (BMN 673) demonstrates excellent potency, inhibiting PARP1 and PARP2 enzyme activity. It inhibits PARP-mediated PARylation in a whole-cell assay and prevents proliferation of cancer cells carrying mutant BRCA1/2. Talazoparib is orally available, displaying favorable pharmacokinetic properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cancer xenograft model following oral administration as a single-agent or in combination with chemotherapy agents such as temozolomide and cisplatin. Medivation (a subsidiary of Pfizer) is developing talazoparib (MDV 3800, formerly BMN 673 and LT 673) for the treatment of genetically defined cancers. On October 16, 2018, the FDA approved talazoparib (TALZENNA, Pfizer Inc.) for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Poly [ADP-ribose] polymerase-1 23 Target ID: CHEMBL3105 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26652717	Inhibitor 8297		1.2 nM [Ki]
Poly [ADP-ribose] polymerase 2 16 Target ID: CHEMBL5366 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26652717	Inhibitor 8297		0.87 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Breast cancer 434 Sources: http://adisinsight.springer.com/drugs/800033477 https://www.ncbi.nlm.nih.gov/pubmed/30506138	Primary	Approved 8429	TALZENNA Approved Use TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. Launch Date 2018
Ovarian cancer 157 Sources: http://adisinsight.springer.com/drugs/800033477	Primary	Phase III 656	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
16.4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.97 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31489639/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
19.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31489639/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TALAZOPARIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
208 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
193 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31489639/	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
196 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31489639/	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TALAZOPARIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
90 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
26% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	1 mg 1 times / day steady-state, oral dose: 1 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TALAZOPARIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 mg 1 times / day steady, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: steady Dose: 1 mg, 1 times / day Sources: https://clincancerres.aacrjournals.org/content/clincanres/25/9/2717.full.pdf	unhealthy, 31 - 75 years n = 84 Health Status: unhealthy Condition: breast cancer Age Group: 31 - 75 years Sex: F Population Size: 84 Sources: https://clincancerres.aacrjournals.org/content/clincanres/25/9/2717.full.pdf	Disc. AE: Anemia, Function liver abnormal... Other AEs: Myelosuppression... AEs leading to discontinuation/dose reduction: Anemia (1 patient) Function liver abnormal (2 patients) Other AEs: Myelosuppression (23 patients) Sources: https://clincancerres.aacrjournals.org/content/clincanres/25/9/2717.full.pdf
1.1 mg 1 times / day multiple, oral MTD Dose: 1.1 mg, 1 times / day Route: oral Route: multiple Dose: 1.1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66	unhealthy, unknown n = 6 Health Status: unhealthy Condition: breast cancer Age Group: unknown Sex: F Population Size: 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66	Disc. AE: Thrombocytopenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (grade 3, 16.67%) Thrombocytopenia (grade 4, 16.67%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66
1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf Page: 6	unhealthy, unknown n = 286 Health Status: unhealthy Condition: breast cancer Age Group: unknown Sex: F Population Size: 286 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf Page: 6	Other AEs: Decreased hemoglobin, Leukocyte count decreased... Other AEs: Decreased hemoglobin (grade 1-4, 90%) Leukocyte count decreased (grade 1-4, 84%) Neutropenia (grade 1-4, 68%) Lymphocyte count low (grade 1-4, 76%) Platelets decreased (grade 1-4, 55%) Glucose increased (grade 1-4, 54%) Aspartate aminotransferase increase (grade 1-4, 37%) Alkaline phosphatase increased (grade 1-4, 36%) Alanine aminotransferase increase (grade 1-4, 33%) Calcium decreased (grade 1-4, 28%) Decreased hemoglobin (grade 3, 39%) Leukocyte count decreased (grade 3, 14%) Neutropenia (grade 3, 17%) Lymphocyte count low (grade 3, 17%) Platelets decreased (grade 3, 11%) Glucose increased (grade 3, 2%) Aspartate aminotransferase increase (grade 3, 2%) Alkaline phosphatase increased (grade 3, 2%) Alanine aminotransferase increase (grade 3, 1%) Calcium decreased (grade 3, 1%) Leukocyte count decreased (grade 4, 0%) Neutropenia (grade 4, 3%) Lymphocyte count low (grade 4, 1%) Platelets decreased (grade 4, 4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf Page: 6
1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 127	unhealthy, unknown n = 286 Health Status: unhealthy Condition: breast cancer Age Group: unknown Sex: F Population Size: 286 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 127	Disc. AE: Anemia, Accidental overdose... AEs leading to discontinuation/dose reduction: Anemia (2%) Accidental overdose (1%) Cerebral hemorrhage (1%) Dyspnea (1%) Glioblastoma multiforme (1%) Headache (1%) Metastases to meninges (1%) Neutropenia (1%) Chronic obstructive airways disease (1%) Thrombocytopenia (1%) Transient ischemic attack (1%) Vomiting (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 127
1 mg 1 times / day multiple, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 128	unhealthy, unknown n = 286 Health Status: unhealthy Condition: breast cancer Age Group: unknown Sex: F Population Size: 286 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 128	Other AEs: Anemia, Neutropenia... Other AEs: Anemia (32%) Neutropenia (15%) Thrombocytopenia (6%) Anemia (>5) Neutropenia (>5) Thrombocytopenia (>5) Platelet count decreased (>5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 128
1 mg 1 times / day steady, oral Recommended Dose: 1 mg, 1 times / day Route: oral Route: steady Dose: 1 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf Page: 5	unhealthy, unknown n = 286 Health Status: unhealthy Condition: breast cancer Age Group: unknown Sex: F Population Size: 286 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf Page: 5	Other AEs: Anemia, Neutropenia... Other AEs: Anemia (grade 1-4, 53%) Neutropenia (grade 1-4, 35%) Thrombocytopenia (grade 1-4, 27%) Decreased appetite (grade 1-4, 21%) Headache (grade 1-4, 33%) Nausea (grade 1-4, 49%) Vomiting (grade 1-4, 25%) Diarrhea (grade 1-4, 22%) Alopecia (grade 1-4, 25%) Fatigue (grade 1-4, 62%) Anemia (grade 3, 38%) Neutropenia (grade 3, 18%) Thrombocytopenia (grade 3, 11%) Decreased appetite (grade 3, <1%) Headache (grade 3, 2%) Nausea (grade 3, <1%) Vomiting (grade 3, 2%) Diarrhea (grade 3, 1%) Fatigue (grade 3, 3%) Anemia (grade 4, 1%) Neutropenia (grade 4, 3%) Thrombocytopenia (grade 4, 4%) Abdominal pain (19%) Dizziness (17%) Leukopenia (17%) Dysgeusia (10%) Dyspepsia (10%) Stomatitis (8%) Lymphopenia (7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf Page: 5

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 781	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP3A4/5 278 UGT1A1 204 UGT1A4 77 UGT1A6 108 UGT1A9 116 UGT2B7 146 UGT2B15 64 BSEP 402	P-gp 1537 BCRP 561 OAT1 326 OAT3 339 OCT1 327 OCT2 355 OATP1B1 406 OATP1B3 350 MATE1 135 MATE2 96 BSEP 52 hepatic enzymes 2	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
BSEP 403	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT1A1 254	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT1A4 80	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT1A6 141	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT1A9 121	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT2B15 64	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no
UGT2B7 157	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
hepatic enzymes 2	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 66.0	minor
BSEP 52	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
MATE1 135	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
MATE2 96	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OAT1 326	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OAT3 339	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OATP1B1 406	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OATP1B3 350	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OCT1 327	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
OCT2 355	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 65.0	no
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 61-62	yes
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31770456/	yes	yes (co-administration study) Comment: itraconazole increases talazoparib AUC >50%; rifampicin did not inrease talazoparib AUC; both increased talazoparib plasma concentrations by 40% and 37%, respectively Sources: https://pubmed.ncbi.nlm.nih.gov/31770456/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf Page: 37.0

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific, Inc. (AKSCI)	X5821	http://www.aksci.com/item_detail.php?cat=X5821
AbMole Bioscience	1732	http://www.abmole.com/product.asp?id=1732
AbMole Bioscience	M1732	http://www.abmole.com/products/bmn673.html
Achemtek	0102-014244	http://www.achemtek.com/1207456-01-6
Acorn PharmaTech	ACN-053048	http://www.acornpharmatech.com/
Ambinter	Amb24093138	http://www.ambinter.com/reference/24093138
ApexBio Technology	A3246	http://www.apexbt.com/bmn-673-8r-9s.html
Aurora Fine Chemicals LLC	K16.649.136	http://online.aurorafinechemicals.com/info?ID=K16.649.136
Aurum Pharmatech LLC	S-7826	http://www.Aurumpharmatech.com/Product/ProductDetails/S_7826
Axon MedChem	2502	https://www.axonmedchem.com/product/2502
BioCrick	BCC2205	http://www.biocrick.com/BMN-673-BCC2205.html
Boerchem	BC600324	http://www.boerchem.com/?product_43159.html
Chem Scene	CS-0937	http://www.chemscene.com/1207456-01-6.html
Chemspace	CSSB00015188901	https://chem-space.com/CSSB00015188901
Chemspace	CSSB00025726212	https://chem-space.com/CSSB00025726212
DC Chemicals	DC2008	http://www.dcchemicals.com/product_show-Talazoparib_BMN_673_.html
Excenen	EX-A1356	http://www.excenen.com/searchresultlist.php?id=1207456-01-6
Lab Network	LN01262559	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01262559
Matrix Scientific	131612	https://www.matrixscientific.com/131612.html
MedChem Express	HY-16106	https://www.medchemexpress.com/BMN-673.html
MolPort	MolPort-042-652-822	https://www.molport.com/shop/molecule-link/MolPort-042-652-822
MuseChem	I000776	https://www.musechem.com/product/I000776.html
Selleck Chemicals	S7048	http://www.selleckchem.com/products/bmn-673.html
Sinfoo Biotech	S061615	http://www.sinfoobiotech.com/product/1065028
Smolecule	S002091	http://www.smolecule.com/products/s002091
Smolecule	S548582	http://www.smolecule.com/products/s548582
Synblock Inc	SB16478	http://www.synblock.com/product/1207456-01-6.html
THE BioTek	bt-253535	https://www.thebiotek.com/product/inhibitors/bt-253535
THE BioTek	bt-287988	https://www.thebiotek.com/product/inhibitors/bt-287988
eNovation Chemicals	D596724	https://www.enovationchem.com/ProductDetails.asp?ProductID=D596724
eNovation Chemicals	Y0974305	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974305
iChemical	EBD2207497	http://www.ichemical.com/products/1207456-01-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
		25795821
PARP inhibitors: A new era of targeted therapy.	2015 May	25708226

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Name

Type

Language

TALAZOPARIB TOSYLATE

Official Name

English

TALAZOPARIB TOSYLATE [USAN]

Common Name

English

BMN 673TS

Code

English

Talazoparib tosylate [WHO-DD]

Common Name

English

TALZENNA

Brand Name

English

(8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one mono(4-methylbenzenesulfonate)

Systematic Name

English

TALAZOPARIB TOSILATE [JAN]

Common Name

English

BMN-673TS

Code

English

TALAZOPARIB TOSYLATE [ORANGE BOOK]

Common Name

English

TALAZOPARIB TOSYLATE [MI]

Common Name

English

3H-PYRIDO(4,3,2-DE)PHTHALAZIN-3-ONE, 5-FLUORO-8-(4-FLUOROPHENYL)-2,7,8,9-TETRAHYDRO-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-, (8S,9R)-, 4-METHYLBENZENESULFONATE (1:1)

Systematic Name

English

TALAZOPARIB TOSILATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C62554